234 related articles for article (PubMed ID: 32250342)
1. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati A; D'Ambrosio M; Troiani M; Mosole S; Pellegrini L; Chen J; Revandkar A; Bolis M; Theurillat JP; Guccini I; Losa M; Calcinotto A; De Bernardis G; Pasquini E; D'Antuono R; Sharp A; Figueiredo I; Nava Rodrigues D; Welti J; Gil V; Yuan W; Vlajnic T; Bubendorf L; Chiorino G; Gnetti L; Torrano V; Carracedo A; Camplese L; Hirabayashi S; Canato E; Pasut G; Montopoli M; Rüschoff JH; Wild P; Moch H; De Bono J; Alimonti A
J Clin Invest; 2020 May; 130(5):2435-2450. PubMed ID: 32250342
[TBL] [Abstract][Full Text] [Related]
2. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L
Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563
[TBL] [Abstract][Full Text] [Related]
3. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.
Dong Y; He Y; de Boer L; Stack MS; Lumley JW; Clements JA; Hooper JD
J Biol Chem; 2012 Mar; 287(13):9792-9803. PubMed ID: 22315226
[TBL] [Abstract][Full Text] [Related]
4. Regulation of inside-out β1-integrin activation by CDCP1.
Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS
Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352
[TBL] [Abstract][Full Text] [Related]
5. CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.
Leroy C; Shen Q; Strande V; Meyer R; McLaughlin ME; Lezan E; Bentires-Alj M; Voshol H; Bonenfant D; Alex Gaither L
Oncogene; 2015 Oct; 34(44):5593-8. PubMed ID: 25728678
[TBL] [Abstract][Full Text] [Related]
6. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.
Casar B; He Y; Iconomou M; Hooper JD; Quigley JP; Deryugina EI
Oncogene; 2012 Aug; 31(35):3924-38. PubMed ID: 22179830
[TBL] [Abstract][Full Text] [Related]
7. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
[TBL] [Abstract][Full Text] [Related]
8. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.
Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J
Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929
[TBL] [Abstract][Full Text] [Related]
9. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
10. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
11. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
13. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.
Jia S; Gao X; Lee SH; Maira SM; Wu X; Stack EC; Signoretti S; Loda M; Zhao JJ; Roberts TM
Cancer Discov; 2013 Jan; 3(1):44-51. PubMed ID: 23258246
[TBL] [Abstract][Full Text] [Related]
14. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.
Szafran AT; Stephan C; Bolt M; Mancini MG; Marcelli M; Mancini MA
Prostate; 2017 Jan; 77(1):82-93. PubMed ID: 27699828
[TBL] [Abstract][Full Text] [Related]
15. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
16. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.
Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A
Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970
[No Abstract] [Full Text] [Related]
17. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.
Yang L; Dutta SM; Troyer DA; Lin JB; Lance RA; Nyalwidhe JO; Drake RR; Semmes OJ
Oncotarget; 2015 Dec; 6(41):43743-58. PubMed ID: 26497208
[TBL] [Abstract][Full Text] [Related]
19. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
20. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]